Neil Woodford’s Risky Portfolio, ft. AstraZeneca plc And Imperial Tobacco Group PLC

AstraZeneca plc (LON:AZN), BT Group plc (LON:BT-A), Rolls-Royce plc (LON: RR) and Imperial Tobacco plc (LON:IMT) are a bet on the M&A cycle…

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

AstraZeneca (LSE: AZN), BT Group (LSE: BT-A), Rolls-Royce (LSE: RR) and Imperial Tobacco (LSE: IMT) account for about 23% of Neil Woodford’s new equity portfolio. BAE Systems, Legal & General and Centrica make up for an additional 7%.

Has Mr Woodford lost his mind? No, he has not. His equity income fund portfolio comprises a total of 61 companies. Sifting through the full list, one may argue that Mr Woodford seems to be betting on the current M&A wave more than on fundamentals, however.

AstraZeneca: How Safe Is It?

Astra is the largest holding (8.3%) in Mr Woodford’s portfolio. Astra is not expected to deliver growth in revenue and earnings for some time. It’s a value play, the bulls argue, for shareholders who believe management will meet their long-term projections.

Astra is virtually debt-free and boasts hefty operating margins, which is typical for large pharmaceutical companies. Its most interesting feature: Astra is still a takeover target for Pfizer. The shares are overpriced by about 20% right now, based on fundamentals, in my view.

GlaxoSmithKline (7.1%) is Mr Woodford’s second-largest holding. GSK is not necessarily an M&A play, yet its assets base may change over time — which could benefit shareholders. And GSK stock is dirt cheap.

Tobacco Consolidation & BT

The tobacco industry is already consolidated, but recent M&A talk has placed the spotlight on Imperial Tobacco, which ranks fifth (5.3%) in Mr Woodford’s portfolio. Meanwhile, British American Tobacco ranks third (6.2%), and could be a consolidator.

Elsewhere, BT ranks fourth (6.02%), and this is probably the most surprising name in the top 10. It’s cheap by most metrics, but it’s hard to fathom why anybody would invest in a business whose revenue growth will barely match inflation in the next couple of years. Decent earnings growth is also in doubt. 

BT is a restructuring play, of course. “With a low beta and a 2.6% dividend yield, BT stock will likely mirror the market trends unless it takes a more aggressive stance on investment at this point in the business cycle,” I argued on 9 May, when BT stock traded at about £3.80. The shares now change hands at £3.82.

Will a change in BT’s corporate structure and/or extraordinary corporate activity provide a fillip to shareholders? Mr Woodford may be betting on these elements. 

More To Do Rolls-Royce 

Rolls ranks ninth (3.47%). I believe the company’s appeal comes from recent corporate activity that proved management were eager to reward shareholders by investing proceeds from asset sales into buybacks. As it shrinks, and more disposals occur, Rolls could become a takeover target, too. It boasts a market cap of about £20bn; Rolls could be swallowed by a larger American rival.

Others….

BAE is included just outside the top 10, which begs the question: is Mr Woodford betting on a merger with EADS? It has been a while since rumours about such a tie-up emerged after a failed attempt in 2012.

There’s a lot to like in Mr Woodford’s approach – transparency, for instance. His defensive portfolio, however, could be riskier than it seems at first glance at this point in the M&A cycle. 

Further down, Legal & General (takeover target), Centrica (takeover target), Smith & Nephew (takeover target), Reckitt (break-up candidate), G4S (takeover target), Serco (takeover target), Meggitt (takeover target), Cobham (takeover target) are just a few companies that could likely be involved in M&A, one way or another.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Alessandro Pasetti has no position in any shares mentioned. The Motley Fool has recommended shares in GlaxoSmithKline and owns shares in Smith & Nephew.

More on Investing Articles

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: our 3 top income-focused stocks to buy before April [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Investing Articles

Is this the best chance to buy cheap FTSE 100 shares in a generation?

I want to buy shares when they're cheap, and sell... never, just keep taking the dividends. And the FTSE 100…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

Could NatWest shares be 2024’s number one buy for passive income?

For those of us looking to earn some long-term passive income, how does NatWest's 7% dividend yield sound? It sounds…

Read more »

Investing Articles

£12K in savings? Here’s how I could turn that into £13K annual passive income

This Fool explains how investing a lump sum can help her build a passive income stream to enjoy in her…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Here’s why Rolls-Royce shares are now set to fly over the £4 mark

Once again, Rolls-Royce shares are crushing the FTSE 100. Should I add to my holding of this stock at the…

Read more »

Investing Articles

1 under the radar FTSE 100 AI stock investors should consider buying

Our writer explains why this FTSE 100 pick could be a shrewd investment with its established experience of using AI…

Read more »

Investing Articles

Does the beaten-down Diageo share price make it a no-brainer buy?

Harvey Jones spent years waiting for the Diageo share price to look like good value, before finally buying it in…

Read more »

One English pound placed on a graph to represent an economic down turn
Investing Articles

8%+ yields! Should I buy these FTSE 100 income shares this month?

Christopher Ruane weighs some pros and cons of two FTSE 100 shares, both of which have a dividend yield over…

Read more »